Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication

被引：0

作者：

Winner, Paul K. ^{[1
]}

Singh, Rashmi B. Halker ^{[2
]}

Cohen, Joshua M. ^{[3
]}

Yang, Ronghua ^{[3
]}

Yeung, Paul P. ^{[3
]}

Ramirez Campos, Verena ^{[4
]}

机构：

[1] Premiere Res Inst, W Palm Beach, FL USA

[2] Mayo Clin, Phoenix, AZ USA

[3] Teva Pharmaceut, Frazer, PA USA

[4] Teva Pharmaceut, Buenos Aires, DF, Argentina

来源：

JOURNAL OF HEADACHE AND PAIN | 2018年 / 19卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

O38

引用

页数：1

共 50 条

[1] Impact of Fremanezumab on Response Rates, Acute Medication Use, and Disability in Patients With Episodic Migraine Who Have Failed at Least One Prior Migraine Preventive Medication
Winner, Paul
Singh, Rashmi Halker
Cohen, Joshua
Yang, Ronghua
Yeung, Paul
Campos, Verena Ramirez
NEUROLOGY, 2019, 92 (15)
[2] Impact of fremanezumab on response rates, acute medication use, and disability in patients with episodic migraine who have failed at least one prior migraine preventive medication (vol 19, 119, 2018)
Winner, Paul K.
Singh, Rashmi B. Halker
Cohen, Joshua M.
Yang, Ronghua
Yeung, Paul P.
Ramirez Campos, Verena
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[3] Impact of Fremanezumab on Response Rates, Migraine Days, and Acute Medication Use in Patients with Chronic Migraine Who Have Failed at Least One Prior Migraine Preventive Medication
Silberstein, Stephen
Ailani, Jessica
Cohen, Joshua
Yang, Ronghua
Yeung, Paul P.
Campos, Verena Ramirez
NEUROLOGY, 2019, 92 (15)
[4] Impact of fremanezumab on response rates, migraine days, and acute medication use in patients with chronic migraine who have failed at least one prior migraine preventive medication
Silberstein, Stephen D.
Ailani, Jessica
Cohen, Joshua M.
Yang, Ronghua
Yeung, Paul P.
Ramirez Campos, Verena
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[5] Efficacy of Fremanezumab in Migraine Patients Who Have Failed at Least One Prior Migraine Preventive Medication
McAllister, Peter
Dodick, David
Cohen, Joshua
Yang, Ronghua
Yeung, Paul
Campos, Verena Ramirez
NEUROLOGY, 2019, 92 (15)
[6] Efficacy of fremanezumab in migraine patients who have failed at least one prior migraine preventive medication
McAllister, Peter
Dodick, David W.
Cohen, Joshua M.
Yang, Ronghua
Yeung, Paul P.
Ramirez Campos, Verena
JOURNAL OF HEADACHE AND PAIN, 2018, 19
[7] Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with episodic migraine who have failed at least one prior preventive migraine medication: results of a 1-year study
Brandes, Jan L.
Smith, Timothy R.
Cohen, Joshua M.
Yang, Ronghua
Ning, Xiaoping
Carr, Karen
CEPHALALGIA, 2019, 39 : 233 - 233
[8] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Episodic Migraine Who Have Failed At least One Prior Preventive Migraine Medication: Results of a 1-Year Study
Brandes, J.
Smith, T. R.
Cohen, J. M.
Yang, R.
Ning, X.
HEADACHE, 2019, 59 : 119 - 120
[9] Long-Term Impact of Fremanezumab on Response Rates, Acute Headache Medication Use, and Disability in Patients with Chronic Migraine Who Have Failed At least One Prior Preventive Migraine Medication: Results of a 1-Year Study
McAllister, P.
Cohen, J. M.
Yang, R.
Ning, X.
HEADACHE, 2019, 59 : 119 - 119
[10] Long-term impact of fremanezumab on response rates, acute headache medication use, and disability in patients with chronic migraine who have failed at least one prior preventive migraine medication: results of a 1-year study
McAllister, Peter
Cohen, Joshua M.
Yang, Ronghua
Ning, Xiaoping
Elms, Shawn
CEPHALALGIA, 2019, 39 : 231 - 232

← 1 2 3 4 5 →